恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床

恒瑞医药2025-09-12

近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。目前国内外尚无同类产品获批上市。　　代谢相关脂肪性肝病（Metabolic dysfunction-associated steatotic liver disease,MASLD，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2566976060?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-12 18:53","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2566976060","market":"fut","top_or_hot":-1,"title":"恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床","media":"恒瑞医药","content":"<div>\n<p>近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。目前国内外尚无同类产品获批上市。　　代谢相关脂肪性肝病（Metabolic dysfunction-associated steatotic liver disease,MASLD，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqfwzh9264722.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-12 18:53 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqfwzh9264722.shtml><strong>恒瑞医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。目前国内外尚无同类产品获批上市。　　代谢相关脂肪性肝病（Metabolic dysfunction-associated steatotic liver disease,MASLD，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqfwzh9264722.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GIPR","symbol_name":"Generation Income Properties Inc.","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-12/doc-infqfwzh9264722.shtml","article_id":"2566976060","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566976060","pubTimestamp":1757674380,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。此外，HRS-4729用于超重/肥胖已获批临床，目前在中国已推进Ⅰ期。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","GIPR":"Generation Income Properties Inc.","BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp","BK4160":"多样化房地产投资信托v","06978":"永泰生物-B","BK4590":"PTP","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Hengrui's Class 1 innovative drug GLP-1R/GIPR/GCGR triple receptor agonist HRS-4729 was approved for clinical use in metabolism-related fatty liver disease/metabolism-related steatohepatitis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"GLP":1,"06978":1,"GIPR":1},"content_text":"近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。目前国内外尚无同类产品获批上市。　　代谢相关脂肪性肝病（Metabolic dysfunction-associated steatotic liver disease,MASLD，原称NAFLD）是遗传易感个体由于营养过剩和胰岛素抵抗引起的慢性进展性肝病。流行病学研究显示，1990至2019年间全球的汇总患病率达30.05%；而我国2018年患病率已达32.9%[1,2]。MASLD与代谢综合征及2型糖尿病互相影响，显著增加肝脏相关临床事件、心血管-肾脏-代谢相关疾病及非肝脏恶性肿瘤的发生风险，导致全因死亡率上升，已成为亟待应对的重大公共健康挑战[3]。　　作为人体能量代谢的重要调节激素，胰高血糖素样肽 1（Glucagon-like peptide-1，GLP-1）、葡萄糖依赖性促胰岛素多肽（Glucose-dependent insulinotropic peptide，GIP）和胰高血糖素（Glucagon，GCG）可在中枢神经系统、胰岛、肠道、肝脏以及脂肪组织等多个器官中激活相应受体，协同调控胰岛素分泌、食欲抑制、能量消耗等多种作用[4,5]。基于这一机制，同时靶向GLP-1、GIP和GCG受体的多激动剂通过多重通路协同作用，不仅显著增强减重与降糖疗效，更在改善肝脏脂质代谢、抑制炎症反应乃至逆转肝纤维化等方面展现出广阔的治疗潜力[6]。　　HRS-4729注射液是恒瑞医药自主研发的1类创新药，是一种GLP-1R/GIPR/GCGR三重受体激动剂。与GLP-1R/GIPR双受体激动剂相比，三受体激动剂在体内调节糖脂代谢、抑制食欲的基础上增加GCGR靶点激活，可进一步增强全身以及肝脏的代谢改善效果，有望为患者与临床医生提供全新的治疗选择。去年5月，公司将包括HRS-4729在内的具有自主知识产权的GLP-1类创新药产品组合在除大中华区以外的全球范围内开发、生产和商业化的独家权利有偿许可给美国Kailera Therapeutics公司，首付款加潜在里程碑付款累计可高达60亿美元，公司还取得Kailera19.9%的股权。此外，HRS-4729用于超重/肥胖已获批临床，目前在中国已推进Ⅰ期。参考文献：　　1.Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347.　　2.Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020 May;71(5):1851-1864.　　3.中华医学会肝病学分会. 代谢相关（非酒精性）脂肪性肝病防治指南（2024年版）. 中华肝脏病杂志,2024,32(5):418-434.　　4.Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-837.　　5.Al-Massadi O, Fern J, Diéguez C, Nogueiras R, Qui ones M. Glucagon Control on Food Intake and Energy Balance. Int J Mol Sci. 2019 Aug 11;20(16):3905.　　6.Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24(3):171-189. 撰稿：程梦真 \n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566976060","isCrawlerRequest":true}